Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII.

In this study, 20 metallocene-based compounds comprising extensive structural diversity were synthesized and evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. These compounds proved moderate to good CA inhibitors in vitro, with several compounds displaying selectivity for cancer-associated isozymes CA IX and CA XII compared to off-target CA I and CA II. Compound 6 was the most potent ferrocene-based inhibitor with K(i)s of 5.9 and 6.8 nM at CA IX and XII, respectively. A selection of key drug-like parameters comprising Log P, Log D, solubility, and in vitro metabolic stability and permeability were measured for two of the ferrocene-based compounds, regioisomers 1 and 5. Compounds 1 and 5 were found to have characteristics consistent with lipophilic compounds, however, our findings show that the lipophilicity of the ferrocene moiety is not well modeled by replacement with either a naphthyl or a phenyl moiety in software prediction tools.

[1]  C. Supuran,et al.  [(Cp-R)M(CO)3] (M=Re or 99mTc) Arylsulfonamide, arylsulfamide, and arylsulfamate conjugates for selective targeting of human carbonic anhydrase IX. , 2012, Angewandte Chemie.

[2]  A. Hofmann,et al.  Protein crystal structures with ferrocene and ruthenocene-based enzyme inhibitors. , 2012, Chemical communications.

[3]  C. Supuran,et al.  Synthesis of glycoconjugate carbonic anhydrase inhibitors by ruthenium-catalysed azide-alkyne 1,3-dipolar cycloaddition. , 2011, Bioorganic & medicinal chemistry letters.

[4]  Claudiu T. Supuran,et al.  Interfering with pH regulation in tumours as a therapeutic strategy , 2011, Nature Reviews Drug Discovery.

[5]  C. Supuran,et al.  Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. , 2011, Journal of medicinal chemistry.

[6]  W Patrick Walters,et al.  What do medicinal chemists actually make? A 50-year retrospective. , 2011, Journal of medicinal chemistry.

[7]  Aamir Ahmad,et al.  Cancer selective metallocenedicarboxylates of the fungal cytotoxin illudin M. , 2011, Journal of medicinal chemistry.

[8]  Tilman Schirmer,et al.  Human carbonic anhydrase II as a host for piano-stool complexes bearing a sulfonamide anchor. , 2011, Chemical communications.

[9]  S. Leung,et al.  Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. , 2011, Cancer research.

[10]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[11]  C. Supuran,et al.  Carbonic anhydrase inhibitors developed through 'click tailing'. , 2010, Current pharmaceutical design.

[12]  P. Dyson,et al.  Bioorganometallic Chemistry — From Teaching Paradigms to Medicinal Applications , 2009 .

[13]  C. Supuran,et al.  Therapeutic applications of glycosidic carbonic anhydrase inhibitors , 2009, Medicinal research reviews.

[14]  C. Supuran,et al.  Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. , 2009, Bioorganic & medicinal chemistry letters.

[15]  Adam R. Urbach,et al.  Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. , 2008, Chemical reviews.

[16]  Brendan L Wilkinson,et al.  Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. , 2008, Journal of medicinal chemistry.

[17]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[18]  C. Supuran,et al.  Inhibition of carbonic anhydrase isozymes I, II and IX with benzenesulfonamides containing an organometallic moiety. , 2007, Bioorganic & medicinal chemistry letters.

[19]  C. Biot,et al.  Ferrocene Conjugates of Chloroquine and other Antimalarials: the Development of Ferroquine, a New Antimalarial , 2007, ChemMedChem.

[20]  Richard D. Vaughan-Jones,et al.  Regulation of tumor pH and the role of carbonic anhydrase 9 , 2007, Cancer and Metastasis Reviews.

[21]  Brendan L Wilkinson,et al.  Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. , 2007, Journal of medicinal chemistry.

[22]  Brendan L Wilkinson,et al.  Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. , 2007, Bioorganic & medicinal chemistry letters.

[23]  Brendan L Wilkinson,et al.  A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". , 2006, Journal of medicinal chemistry.

[24]  Santoshkumar N. Patil,et al.  An Easy Access to Aryl Azides from Aryl Amines under Neutral Conditions. , 2005 .

[25]  N. Metzler‐Nolte,et al.  Bioorganometallic chemistry of ferrocene. , 2004, Chemical reviews.

[26]  G. Leclercq,et al.  Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer ce , 2003, Chemistry.

[27]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[28]  C. Bevan,et al.  A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. , 2000, Analytical chemistry.

[29]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[30]  V. Rotello,et al.  Fluorocarbonylferrocene. A Versatile Intermediate for Ferrocene Esters and Amides. , 1999, The Journal of organic chemistry.

[31]  H. Köpf,et al.  Ferrocenium Salts—The First Antineoplastic Iron Compounds , 1984 .

[32]  J. Pouysségur,et al.  Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.

[33]  F. Lombardo,et al.  ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. , 2001, Journal of medicinal chemistry.

[34]  M. Abraham,et al.  Solvation descriptors for ferrocene, and the estimation of some physicochemical and biochemical properties , 2000 .

[35]  E. Fischer,et al.  The Aromatic Reactivity of Ferrocene, Ruthenocene and Osmocene1,2 , 1960 .